Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364502 · ClinicalTrials.gov registry record · NA
(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds
A NA study of Arterial Bleeding in Solid Organs and Peripheral Arteries, sponsored by Instylla.
- Active
- Registry status
- NA
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT05364502 is a NA study of Arterial Bleeding in Solid Organs and Peripheral Arteries that is active but no longer recruiting, run by Instylla. The registered enrollment target is 130 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05364502, a NA study of Arterial Bleeding in Solid Organs and Peripheral Arteries, is active but no longer recruiting, sponsored by Instylla.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
Conditions Studied
Interventions
- DEVICE Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter
Study Locations (20)
California
- Memorial Health Services - Long Beach
- Stanford University - Stanford
- UCLA Harbor Lindquist Institute - Torrance
Connecticut
- Nuvance Health - Danbury
- Yale University - New Haven
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Medical Center - Boston
New York
- Mount Sinai Hospital - New York
- Columbia University Milstein - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh - Pittsburgh
Arizona
- Banner Health - Phoenix
District of Columbia
- Medstar Georgetown University - Washington D.C.
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05364502
The ClinicalTrials.gov registry entry for NCT05364502 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Instylla, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arterial Bleeding in Solid Organs and Peripheral Arteries appearing as the primary indexed condition, and to 1 intervention - of which Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter is the first listed.
NCT05364502 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05364502 about?
NCT05364502 is a clinical study titled "(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds". To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.
What is the current status of trial NCT05364502?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2022-12-12. Estimated completion is 2026-03.
What conditions does trial NCT05364502 study?
This clinical trial studies the following conditions: Arterial Bleeding in Solid Organs and Peripheral Arteries.
What interventions are being tested in trial NCT05364502?
The interventions under investigation include: Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter (DEVICE).
Who is sponsoring clinical trial NCT05364502?
This trial is sponsored by Instylla, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05364502 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.